ScoreWhy is Teyi Pharmaceutical Group Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 5.32% and Operating profit at -8.81% over the last 5 years
2
Flat results in Mar 26
- NET SALES(Q) At CNY 209.87 MM has Fallen at -28.89%
- DEBTORS TURNOVER RATIO(HY) Lowest at 3.95 times
3
With ROE of 4.11%, it has a fair valuation with a 1.67 Price to Book Value
- Over the past year, while the stock has generated a return of -2.67%, its profits have risen by 76.8% ; the PEG ratio of the company is 0.5
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -2.67% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Teyi Pharmaceutical Group Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Teyi Pharmaceutical Group Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Teyi Pharmaceutical Group Co., Ltd.
-100.0%
-0.04
45.90%
China Shanghai Composite
21.43%
1.73
13.79%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
5.32%
EBIT Growth (5y)
-8.81%
EBIT to Interest (avg)
8.54
Debt to EBITDA (avg)
0.88
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.39
Tax Ratio
14.65%
Dividend Payout Ratio
91.74%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.69%
ROE (avg)
9.04%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
41
Industry P/E
Price to Book Value
1.67
EV to EBIT
43.53
EV to EBITDA
24.94
EV to Capital Employed
1.70
EV to Sales
3.62
PEG Ratio
0.53
Dividend Yield
0.52%
ROCE (Latest)
3.90%
ROE (Latest)
4.11%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 167.18 MM
NET PROFIT(9M)
Higher at CNY 69.43 MM
-7What is not working for the Company
NET SALES(Q)
At CNY 209.87 MM has Fallen at -28.89%
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.95 times
Here's what is working for Teyi Pharmaceutical Group Co., Ltd.
Net Profit
At CNY 69.43 MM has Grown at 40.62%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 167.18 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Profit
Higher at CNY 69.43 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Profit (CNY MM)
Here's what is not working for Teyi Pharmaceutical Group Co., Ltd.
Net Sales
At CNY 209.87 MM has Fallen at -28.89%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely negative
Net Sales (CNY MM)
Debtors Turnover Ratio
Lowest at 3.95 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
